ReShape Lifesciences Notice of Allowance for Added U.S. Patent on Diabetes Neuromodulation Tech

ReShape Lifesciences (RSLS) has received a USPTO Notice of Allowance for patent application 18/069,689, titled 'High-Frequency Low Duty Cycle Patterns for Neural Regulation', providing protection until August 2037. The patent covers their Diabetes Neuromodulation system which utilizes proprietary vBloc™ technology for treating Type 2 diabetes through vagal nerve modulation.

The technology features an energy-efficient algorithm that uses discontinuous high-frequency signals with interwoven micro- and millisecond pauses, consuming 10 times less energy than traditional continuous signals. Preclinical testing on rat vagus nerves has shown equivalent efficacy while remaining compatible with standard implantable pulse generators.

The company's intellectual property portfolio includes 63 issued or pending patents covering vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.

https://www.stocktitan.net/news/RSLS/re-shape-lifesciences-receives-notice-of-allowance-for-additional-u-c8kfb326k05k.html